Forensic dye analysis in cultural heritage: Unraveling the authenticity of the earliest Persian knotted-pile silk carpet.

The use of forensic dye analysis in the field of cultural heritage is introduced, and a case study is presented determining the dating of a potentially important textile fragment from the Cleveland Museum of Art. The fragment, attributed on stylistic grounds to the 15th century, is purportedly the oldest surviving example of a Persian knotted-pile silk carpet. Raman spectroscopy combined with liquid chromatography - mass spectrometry determined the dyes used in the fragment include Metanil yellow, Congo red, and indigo, possibly in its synthetic form. Based on the dates of introduction for these dyes (1879, 1884, and 1897, respectively) and the first appearance of the textile fragment in 1928, the object is shown to be almost certainly a late 19th or early 20th century creation. Furthermore, impurities found in the red dye are suggested as potential markers of a pre-1970s synthetic route for manufacturing Congo red or possibly degraded Congo red due to environmental pollutants.

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.

LY2603618 is an inhibitor of checkpoint kinase 1 (CHK1), an important regulator of the DNA damage checkpoints. Preclinical experiments analyzed NCI-H2122 and NCI-H441 NSCLC cell lines and in vitro/in vivo models treated with pemetrexed and LY2603618 to provide rationale for evaluating this combination in a clinical setting. Combination treatment of LY2603618 with pemetrexed arrested DNA synthesis following initiation of S-phase in cells. Experiments with tumor-bearing mice administered the combination of LY2603618 and pemetrexed demonstrated a significant increase of growth inhibition of NCI-H2122 (H2122) and NCI-H441 (H441) xenograft tumors. These data informed the clinical assessment of LY2603618 in a seamless phase I/II study, which administered pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) and escalating doses of LY2603618: 130-275 mg. Patients were assessed for safety, toxicity, and pharmacokinetics. In phase I, 14 patients were enrolled, and the most frequently reported adverse events included fatigue, nausea, pyrexia, neutropenia, and vomiting. No DLTs were reported at the tested doses. The systemic exposure of LY2603618 increased in a dose-dependent manner. Pharmacokinetic parameters that correlate with the maximal pharmacodynamic effect in nonclinical xenograft models were achieved at doses ≥240 mg. The pharmacokinetics of LY2603618, pemetrexed, and cisplatin were not altered when used in combination. Two patients achieved a confirmed partial response (both non-small cell lung cancer), and 8 patients had stable disease. LY2603618 administered in combination with pemetrexed and cisplatin demonstrated an acceptable safety profile. The recommended phase II dose of LY2603618 was 275 mg.

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

PURPOSE: To investigate the toxicity profile, activity, pharmacokinetics, and pharmacodynamics of pemetrexed in leukemia. PATIENTS AND METHODS: Patients with refractory or relapsed acute leukemia were eligible. A phase I 3+3 design was implemented. Pemetrexed was infused intravenously (IV) over 25 min with vitamin supplementation. Courses were repeated every 3 to 4 weeks according to toxicity and efficacy. The starting dose of 900 mg/m² was escalated by approximately 33% until the dose-limiting toxicity (DLT) was determined. RESULTS: Twenty patients with acute myeloid (AML) or lymphocytic (ALL) leukemia received therapy. The main non-hematologic adverse event was liver dysfunction at several dose levels, including 2 DLTs at 3,600 mg/m². One patient with ALL (3,600 mg/m² dose level) achieved a partial response. Pemetrexed pharmacokinetics were linear with escalated dosing. Elevated plasma deoxyuridine was observed in a subset of patients following pemetrexed infusion, but was not correlated with dose levels. Changes in the nucleotide pools of circulating mononuclear cells were observed, but were variable. CONCLUSIONS: The recommended phase II dose of pemetrexed for future leukemia studies is 2,700 mg/m(2) IV over 25 min every 3 to 4 weeks with vitamin supplementation. Deoxyuridine levels did not increase with increasing pemetrexed dose, suggesting pemetrexed inhibition of thymidylate synthase (TS) may be saturated by the 900 mg/m² dose level. However, no firm conclusion can be made regarding TS saturation in tumor cells. While tolerable, pemetrexed monotherapy had limited activity in this highly refractory population. Exploration of pemetrexed in combination with other active agents in leukemia is a reasonable future endeavor.

Comparative evaluation of nanofibrous scaffolding for bone regeneration in critical-size calvarial defects.

In a previous study we found that nanofibrous poly(l-lactic acid) (PLLA) scaffolds mimicking collagen fibers in size were superior to solid-walled scaffolds in promoting osteoblast differentiation and bone formation in vitro. In this study we used an in vivo model to confirm the biological properties of nanofibrous PLLA scaffolds and to evaluate how effectively they support bone regeneration against solid-walled scaffolds. The scaffolds were implanted in critical-size defects made on rat calvarial bones. Compared with solid-walled scaffolds, nanofibrous scaffolds supported substantially more new bone tissue formation, which was confirmed by micro-computed tomography measurement and von Kossa staining. Goldner's trichrome staining showed abundant collagen deposition in nanofibrous scaffolds but not in the control solid-walled scaffolds. The cells in these scaffolds were immuno-stained strongly for Runx2 and bone sialoprotein (BSP). In contrast, solid-walled scaffolds implanted in the defects were stained weakly with trichrome, Runx2, and BSP. These in vivo results demonstrate that nanofibrous architecture enhances osteoblast differentiation and bone formation.

Derivation and characterization of monoclonal antibodies against human folypolyglutamate synthetase.

Folypolyglutamate synthetase (FPGS) plays a critical role in the cellular retention of both folates and antifolates. Resistance to antifolates is in part related to changes in FPGS enzyme activity and levels of messenger RNA, or in some instances, protein as evaluated by Western blots using polyclonal antisera. The present study was designed to derive a series of monoclonal antibodies (MAb) against the native protein, to characterize them in terms of specificity and epitope mapping, and to determine kinetic constants by Biacore. We report on 3 IgG(1) kappa MAbs-namely, 4-2, 4-3, and 4-18-with epitopes localized to the carboxyl domain of the protein. These antibodies recognize a single band on Western blots of HeLa cell lysates, which is significantly reduced following RNAi knockdown. The recognition of both the native and denatured conformations of FPGS by these MAbs should provide useful reagents for FPGS quantitation in either tumor cell lysates or in tumor biopsies.

Nano-fibrous scaffolding promotes osteoblast differentiation and biomineralization.

Nano-fibrous poly(L-lactic acid) (PLLA) scaffolds with interconnected pores were developed under the hypothesis that nano-fibrous scaffolding would mimic a morphological function of collagen fibrils to create a more favorable microenvironment for cells versus solid-walled scaffolds. In this study, an in vitro system was used to examine biological properties of the nano-fibrous scaffolds compared with those of solid-walled scaffolds for their potential use in bone tissue engineering. Biomineralization was enhanced substantially on the nano-fibrous scaffolds compared to solid-walled scaffolds, and this was confirmed by von Kossa staining, measurement of calcium contents, and transmission electron microscopy. In support of this finding, osteoblasts cultured on the nano-fibrous scaffolds exhibited higher alkaline phosphatase activity and an earlier and enhanced expression of the osteoblast phenotype versus solid-walled scaffolds. Most notable were the increases in runx2 protein and in bone sialoprotein mRNA in cells cultured on nano-fibrous scaffolds versus solid-walled scaffolds. At the day 1 of culture, alpha2 and beta1 integrins as well as alphav and beta3 integrins were highly expressed on the surface of cells seeded on nano-fibrous scaffolds, and linked to this were higher levels of phospho-Paxillin and phospho-FAK in cell lysates. In contrast, cells seeded on solid-walled scaffolds expressed significantly lower levels of these integrins, phospho-Paxillin, and phospho-FAK. To further examine the role of nano-fibrous architecture, we inhibited the formation of collagen fibrils by adding 3,4-dehydroproline to cultures and then assayed cells for expression of alpha2 integrin. Cells seeded on nano-fibrous scaffolds sustained expression of alpha2 integrin in the presence of dehydroproline, while suppression of alpha2 integrin was evident in cells seeded on solid-walled scaffolds. These results provide initial evidence that synthetic nano fibers may exhibit certain properties that are comparable to natural collagen fibers, and thus, the nano-fibrous architecture may serve as a superior scaffolding versus solid-walled architecture for promoting osteoblast differentiation and biomineralization.

Derivation and characterization of a monoclonal antibody against human glycinamide ribonucleotide formyltransferase.

Glycinamide ribonucleotide formyltransferase (GARFT) is a trifunctional enzyme involved in purine biosynthesis. Its central role in folate metabolism has made it an obvious target for the development of GARFT inhibitors, primarily for oncology. While the crystal structure, enzyme kinetics, and mechanism of action of GARFT inhibitors are reasonably well understood, GARFT regulation at the protein level remains unclear. The present study reports the development and characterization of a monoclonal antibody (MAb) specific for human GARFT. This MAb, an IgG1kappa, designated PHR1, recognizes human GARFT by both Western blot and by immunohistochemistry from non-small-cell lung carcinoma and colon adenocarcinoma tissue biopsies, has a KD of 1.14 x 10(10) M, and has been epitope mapped at residues 59-78 of the GARFT functional domain. The ability of PHR1 to recognize both sodium dodecyl sulfate (SDS)-denatured as well as native GARFT should make this MAb an important research tool in determining GARFT protein levels in both normal and neoplastic tissues.

Bone regeneration on computer-designed nano-fibrous scaffolds.

The ability to control architectural features in tissue engineering scaffolds is critical to the success of neo-tissue regeneration. In this work, reverse solid freeform fabrication and thermal phase separation of poly(L-lactic acid) (PLLA) solutions were used to create three-dimensional nano-fibrous (NF) scaffolds with complex geometries on the macro- and micro-scales. This approach allows for the fabrication of NF matrices while having precise control of internal pore size and structure, as well as external scaffold shape including architectures generated from computed-tomography scans and histological sections. In vitro cell cultivation experiments with MC3T3-E1 pre-osteoblasts were performed on NF scaffolds and on similarly designed solid-walled (SW) scaffolds that did not have nano-fibers. Proliferation studies showed significantly more cells on NF scaffolds after 7 d. In differentiation studies, the NF scaffolds displayed more uniform matrix and mineral production throughout. Real-time PCR also showed significantly higher expression of osteocalcin and bone sialoprotein mRNAs after 2 and 6 weeks in the NF scaffolds. Expression of type I collagen mRNA was lower in NF scaffolds which possibly indicates quicker differentiation on the NF substrate. In summary, we controlled the geometry of NF PLLA scaffolds at multiple size scales, and the in vitro results showed that these NF scaffolds were advantageous to control scaffolds for bone tissue engineering.

The effect of surface area on the degradation rate of nano-fibrous poly(L-lactic acid) foams.

In vitro hydrolytic degradation behavior was examined for nano-fibrous (NF) poly(L-lactic acid) (PLLA) foams prepared by phase separation. NF foams were incubated in phosphate-buffered saline at 37 degrees C for 15 months. Upon removal, changes in mass, molar mass, morphology, BET specific surface area, mechanical properties, and thermal properties were compared with those of similarly incubated solid-walled (SW) PLLA foams. Initial surface area in NF foams was over 80 times higher than in SW foams. During incubation, NF surface area decreased steadily, only possessing 17% of the original specific surface area after 15 months, SW surface area stayed constant throughout. While molar mass decreased for both types of samples, degradation was much more rapid in NF foams. In NF foams, overall mass loss was 51% while mass loss in SW foams was only 6% after 15 months. Morphology of NF foams began as a mesh of fibers, and became increasingly porous as fibers began to aggregate, thus diminishing the mechanical properties. In SW foams, morphology was non-fibrous and remained unchanged which helped maintain their mechanical properties. These results suggest that the high surface area in NF foams accelerated the rate of hydrolytic degradation.

A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression.

PURPOSE: This phase II trial of pemetrexed explored potential correlations between treatment outcome (antitumor activity) and molecular target expression. EXPERIMENTAL DESIGN: Chemonaïve patients with advanced breast cancer received up to three cycles of pemetrexed 500 mg/m2 (10-minute i.v. infusion) on day 1 of a 21-day cycle, with folic acid and vitamin B12 supplementation. Tumors were surgically removed after the last cycle of pemetrexed as clinically indicated. Biopsies were taken at baseline, 24 hours after infusion in cycle 1, and after cycle 3. RESULTS: Sixty-one women (median age, 46 years; range, 32-72 years) were treated and were evaluable for response. Objective response rate was 31%. Simple logistic regression suggested a potential relationship between mRNA expression of thymidylate synthase (TS) and pemetrexed response (P = 0.103). Based on threshold analysis, patients with "low" baseline TS (< or = 71) were more likely to respond to pemetrexed than patients with "high" baseline TS (>71). Expression of baseline dihydrofolate reductase and glycinamide ribonucleotide formyl transferase tended to be higher in responders but this association was not significant (P > 0.311). TS expression increased significantly between baseline and biopsy 2 (P = 0.004) and dropped to near baseline levels at biopsy 3. Conversely, dihydrofolate reductase and glycinamide ribonucleotide formyl transferase decreased after pemetrexed chemotherapy. CONCLUSIONS: Our results suggest a potential association between "low" pretreatment TS expression levels and response to pemetrexed chemotherapy. Future trials examining expression levels of other genes important to the folate pathway and/or breast cancer may identify a more robust multigene profile that can better predict response to this novel antifolate.

Nano-fibrous poly(L-lactic acid) scaffolds with interconnected spherical macropores.

Biodegradable polymers have been used extensively as scaffolding materials to regenerate new tissues. These scaffolds should possess certain physical characteristics including a three-dimensional structure, high porosity with an interconnected pore structure, and a suitable surface structure for cell attachment, proliferation, and differentiation. To mimic the fibrous architecture of type I collagen, nano-fibrous matrices have been created in our laboratory using a phase-separation technique of poly(L-lactic acid) (PLLA) solutions. In addition, biodegradable scaffolds with controlled interconnected spherical pore networks have been fabricated in our laboratory. In this work, these two techniques were combined to yield scaffolds with highly interconnected spherical macroporous structures and nano-fibrous architectures. Paraffin spheres were first fabricated with a dispersion method, and were thermally bonded to form an interconnected mold. PLLA solutions were cast over the paraffin sphere assembly and were thermally phase-separated to form nano-fibrous matrices. After leaching out the paraffin, synthetic nano-fibrous extracellular matrices with interconnected spherical pores were yielded. By utilizing this fabrication process, we are able to control the architecture of the scaffolds at several different levels, including the macroscopic shape of the scaffold, the spherical pore size, interfiber distance, and the fiber diameter at the nano-size scale. The inter-pore connectivity could be controlled by varying the heat treatment time of the paraffin spheres, and mechanical properties could be controlled by varying the porosity of the scaffolds. With an interconnected macroporous structure that promotes cell seeding throughout the interstices of the scaffold, and a synthetic collagen-like matrix, these novel matrices may be an excellent scaffold for tissue engineering.

Nano-fibrous scaffolding architecture selectively enhances protein adsorption contributing to cell attachment.

Tissue engineering aims at resolving problems such as donor shortage and immune rejection faced by transplantation. Scaffolds (artificial extracellular matrices) have critical roles in tissue engineering. Recently, we developed nano-fibrous poly(L-lactic acid) scaffolds under the hypothesis that synthetic nano-fibrous scaffolding, mimicking the structure of natural collagen fibers, could create a more favorable microenvironment for cells. This is the first report that the nano-fibrous architecture built in three-dimensional scaffolds improved the features of protein adsorption, which mediates cell interactions with scaffolds. Scaffolds with nano-fibrous pore walls adsorbed four times more serum proteins than scaffolds with solid pore walls. More interestingly, the nano-fibrous architecture selectively enhanced protein adsorption including fibronectin and vitronectin, even though both scaffolds were made from the same poly(L-lactic acid) material. Furthermore, nano-fibrous scaffolds also allowed >1.7 times of osteoblastic cell attachment than scaffolds with solid pore walls. These results demonstrate that the biomimetic nano-fibrous architecture serves as superior scaffolding for tissue engineering.